{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:37:21Z","timestamp":1787060241345,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T00:00:00Z","timestamp":1309392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T00:00:00Z","timestamp":1309392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s12325-011-0038-9","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T01:59:20Z","timestamp":1309744760000},"page":"575-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension"],"prefix":"10.1007","volume":"28","author":[{"given":"Carl","family":"Erb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seid-Fatima","family":"Seidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,30]]},"reference":[{"key":"38_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"H.A. Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u2013267.","journal-title":"Br J Ophthalmol"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"M.C. Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment Trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"38_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"AGIS Investigators.","year":"2000","unstructured":"AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u2013440.","journal-title":"Am J Ophthalmol"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A. Heijl","year":"2002","unstructured":"Heijl, A, Leske, MC, Bengtsson, B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u20131279.","journal-title":"Arch Ophthalmol"},{"key":"38_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group.","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487\u2013497.","journal-title":"Am J Ophthalmol"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"M.A. Kass","year":"2002","unstructured":"Kass, MA, Heuer, DK, Higginbotham, EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u2013713.","journal-title":"Arch Ophthalmol"},{"issue":"Suppl.1","key":"38_CR7","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.survophthal.2008.08.012","volume":"53","author":"G.W. Bean","year":"2008","unstructured":"Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008; 53(Suppl. 1):S69\u2013S84.","journal-title":"Surv Ophthalmol"},{"key":"38_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","volume":"78","author":"Y. Takagi","year":"2004","unstructured":"Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 2004;78:767\u2013776.","journal-title":"Exp. Eye Res."},{"key":"38_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/jop.2009.0066","volume":"26","author":"C.E. Traverso","year":"2010","unstructured":"Traverso CE, Ropo A, Papadia M, et al. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97\u2013104.","journal-title":"J Ocul Pharmacol Ther"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-3768.2008.01381.x","volume":"242","author":"T. Hamacher","year":"2008","unstructured":"Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242:14\u201319.","journal-title":"Acta Ophthalmol Suppl (Oxf)"},{"key":"38_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","volume":"88","author":"H. Uusitalo","year":"2010","unstructured":"Uusitalo H, Pillunat LE, Ropo A, et al. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12\u201319.","journal-title":"Acta Ophthalmol"},{"key":"38_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/00055735-199604000-00014","volume":"7","author":"C. Baudouin","year":"1996","unstructured":"Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80\u201386.","journal-title":"Curr Opin Ophthalmol"},{"key":"38_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02713680801971857","volume":"33","author":"E. Brasnu","year":"2008","unstructured":"Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303\u2013312.","journal-title":"Curr Eye Res"},{"key":"38_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2008.10.019","volume":"147","author":"G. Martone","year":"2009","unstructured":"Martone, G, Frezzotti P, Tosi GM et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725\u2013735.","journal-title":"Am J Ophthalmol"},{"key":"38_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jfo.2010.06.018","volume":"33","author":"D. Vaede","year":"2010","unstructured":"Vaede D, Caudouin C, Warnet JM, et al. Preservatives in eyedrops: toward awareness of their toxicity. J Fr Ophthalmol. 2010;33:505\u2013524.","journal-title":"J Fr Ophthalmol"},{"key":"38_CR16","first-page":"29","volume":"16","author":"C. Baudoin","year":"1996","unstructured":"Baudoin C. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res. 1996;16:29\u201341.","journal-title":"Int J Clin Pharmacol Res"},{"key":"38_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C. Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin Eye Res. 2010;29:312\u2013334.","journal-title":"Prog. Retin Eye Res"},{"key":"38_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","volume":"246","author":"C. Erb","year":"2008","unstructured":"Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593\u2013601.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"38_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"E.W. Leung","year":"2008","unstructured":"Leung EW, Kedeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350\u2013355.","journal-title":"J Glaucoma"},{"key":"38_CR20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","volume":"19","author":"G.C. Rossi","year":"2009","unstructured":"Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572\u2013579.","journal-title":"Eur J Ophthalmol"},{"key":"38_CR21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"R.D. Fechtner","year":"2010","unstructured":"Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressurelowering medications. Cornea. 2010;29:618\u2013621.","journal-title":"Cornea"},{"key":"38_CR22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","volume":"88","author":"H. Uusitalo","year":"2010","unstructured":"Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329\u2013336.","journal-title":"Acta Ophthalmol"},{"key":"38_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1185\/03007995.2010.492030","volume":"26","author":"A. Hommer","year":"2010","unstructured":"Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905\u20131913.","journal-title":"Curr Med Res Opin"},{"key":"38_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","volume":"25","author":"M.Y. Kahook","year":"2008","unstructured":"Kahook, MY, Noecker, R Quantitative analysis of conjunctival goblet cells after chronic application of topical drugs. Adv Ther. 2008;25:743\u2013751.","journal-title":"Adv Ther"},{"key":"38_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C. Baudouin","year":"2008","unstructured":"Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716\u2013726.","journal-title":"Acta Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-011-0038-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12325-011-0038-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T07:21:30Z","timestamp":1724397690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-011-0038-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,30]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s12325-011-0038-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,30]]},"assertion":[{"value":"15 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2011","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}